Biotech company Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM) (PHARM.AS) announced today that it has raised EUR 17.1 million from new institutional investors for the further development of recombinant human C1 inhibitor (rhC1INH).
